<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29901583</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.</ArticleTitle>
        <Pagination>
          <StartPage>e10932</StartPage>
          <MedlinePgn>e10932</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e10932</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000010932</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Paraneoplastic limbic encephalitis (PLE) is a rare disorder of the nervous system associated with malignant disease. It has a subacute onset with the following symptoms: cognitive dysfunction, seizures, irritability, hallucinations, and short-term memory loss. Herein, we report the case of a 35-year-old man with PLE, an olfactory neuroblastoma (ONB) admixed with craniopharyngioma, and serum anti-Hu antibodies.</AbstractText>
          <AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">The patient presented with generalized seizures, short-term memory loss, and a polypoid mass located high in the nasal cavity.</AbstractText>
          <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">He underwent surgical resection of the tumor and postoperative chemoradiotherapy with concurrent intra-arterial cisplatin administration.</AbstractText>
          <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Pathological examination indicated an ONB admixed with craniopharyngioma.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">The patient's neurological symptoms gradually diminished after surgery. No evidence of recurrence was observed during a 4-year follow-up.</AbstractText>
          <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">We reported a histologically unusual heterogeneous tumor that comprised ONB and craniopharyngioma. This is the first reported case of PLE with anti-Hu antibodies possibly associated with ONB admixed with craniopharyngioma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nagafuji</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine, Tokyo, Japan Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yokoi</LastName>
            <ForeName>Hidenori</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujiwara</LastName>
            <ForeName>Masachika</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Dai</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saito</LastName>
            <ForeName>Koichiro</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Medicine (Baltimore). 2018 Jul;97(28):e11575</RefSource>
          <PMID Version="1">29995829</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003397" MajorTopicYN="N">Craniopharyngioma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018304" MajorTopicYN="N">Esthesioneuroblastoma, Olfactory</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009296" MajorTopicYN="N">Nasal Cavity</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059747" MajorTopicYN="N">Nasal Surgical Procedures</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009669" MajorTopicYN="N">Nose Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no funding and conflicts of interest to disclose .</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29901583</ArticleId>
        <ArticleId IdType="pmc">PMC6024189</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000010932</ArticleId>
        <ArticleId IdType="pii">00005792-201806150-00011</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darnell RB, Posner JB.
Paraneoplastic syndromes involving the nervous system. N Engl J Med
2003;349:1543–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al. 
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain
2000;123:1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinschmidt-DeMasters BK, Pflaumer SM, Mulgrew TD, et al. 
Sinonasal teratocarcinosarcoma (“mixed olfactory neuroblastoma-craniopharyngioma”) presenting with syndrome of inappropriate secretion of antidiuretic hormone. Clin Neuropathol
2000;19:63–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. 
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry
2004;75:1135–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faragalla H, Weinreb I.
Olfactory neuroblastoma: a review and update. Adv Anat Pathol
2009;16:322–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19700942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DC, Goodman ML, Pilch BZ, et al. 
Mixed olfactory neuroblastoma and carcinoma. A report of two cases. Cancer
1984;54:2019–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6206941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang KC, Jin YT, Chen RM, et al. 
Mixed olfactory neuroblastoma and craniopharyngioma: an unusual pathological finding. Histopathology
1997;30:378–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9147090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finzi G, Cerati M, Marando A, et al. 
Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary
2014;17:53–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23344977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viaccoz A, Honnorat J.
Paraneoplastic neurological syndromes: general treatment overview. Curr Treat Options Neurol
2013;15:150–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23436113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croteau D, Owainati A, Dalmau J, et al. 
Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology
2001;57:719–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11524490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keime-Guibert F, Graus F, Fleury A, et al. 
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry
2000;68:479–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736897</ArticleId>
            <ArticleId IdType="pubmed">10727484</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29901583</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.</ArticleTitle>
        <Pagination>
          <StartPage>e10932</StartPage>
          <MedlinePgn>e10932</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e10932</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000010932</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Paraneoplastic limbic encephalitis (PLE) is a rare disorder of the nervous system associated with malignant disease. It has a subacute onset with the following symptoms: cognitive dysfunction, seizures, irritability, hallucinations, and short-term memory loss. Herein, we report the case of a 35-year-old man with PLE, an olfactory neuroblastoma (ONB) admixed with craniopharyngioma, and serum anti-Hu antibodies.</AbstractText>
          <AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">The patient presented with generalized seizures, short-term memory loss, and a polypoid mass located high in the nasal cavity.</AbstractText>
          <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">He underwent surgical resection of the tumor and postoperative chemoradiotherapy with concurrent intra-arterial cisplatin administration.</AbstractText>
          <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Pathological examination indicated an ONB admixed with craniopharyngioma.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">The patient's neurological symptoms gradually diminished after surgery. No evidence of recurrence was observed during a 4-year follow-up.</AbstractText>
          <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">We reported a histologically unusual heterogeneous tumor that comprised ONB and craniopharyngioma. This is the first reported case of PLE with anti-Hu antibodies possibly associated with ONB admixed with craniopharyngioma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nagafuji</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, Kyorin University School of Medicine, Tokyo, Japan Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yokoi</LastName>
            <ForeName>Hidenori</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujiwara</LastName>
            <ForeName>Masachika</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Dai</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saito</LastName>
            <ForeName>Koichiro</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Medicine (Baltimore). 2018 Jul;97(28):e11575</RefSource>
          <PMID Version="1">29995829</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003397" MajorTopicYN="N">Craniopharyngioma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018304" MajorTopicYN="N">Esthesioneuroblastoma, Olfactory</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009296" MajorTopicYN="N">Nasal Cavity</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059747" MajorTopicYN="N">Nasal Surgical Procedures</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009669" MajorTopicYN="N">Nose Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no funding and conflicts of interest to disclose .</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29901583</ArticleId>
        <ArticleId IdType="pmc">PMC6024189</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000010932</ArticleId>
        <ArticleId IdType="pii">00005792-201806150-00011</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darnell RB, Posner JB.
Paraneoplastic syndromes involving the nervous system. N Engl J Med
2003;349:1543–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al. 
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain
2000;123:1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinschmidt-DeMasters BK, Pflaumer SM, Mulgrew TD, et al. 
Sinonasal teratocarcinosarcoma (“mixed olfactory neuroblastoma-craniopharyngioma”) presenting with syndrome of inappropriate secretion of antidiuretic hormone. Clin Neuropathol
2000;19:63–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10749286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. 
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry
2004;75:1135–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faragalla H, Weinreb I.
Olfactory neuroblastoma: a review and update. Adv Anat Pathol
2009;16:322–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19700942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller DC, Goodman ML, Pilch BZ, et al. 
Mixed olfactory neuroblastoma and carcinoma. A report of two cases. Cancer
1984;54:2019–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6206941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang KC, Jin YT, Chen RM, et al. 
Mixed olfactory neuroblastoma and craniopharyngioma: an unusual pathological finding. Histopathology
1997;30:378–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9147090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finzi G, Cerati M, Marando A, et al. 
Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary
2014;17:53–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23344977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viaccoz A, Honnorat J.
Paraneoplastic neurological syndromes: general treatment overview. Curr Treat Options Neurol
2013;15:150–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23436113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croteau D, Owainati A, Dalmau J, et al. 
Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology
2001;57:719–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11524490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keime-Guibert F, Graus F, Fleury A, et al. 
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry
2000;68:479–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736897</ArticleId>
            <ArticleId IdType="pubmed">10727484</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
